Setmelanotide is a prescription medication used to treat obesity caused by rare genetic disorders such as pro-opiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS). It is administered as an injection under the skin (subcutaneous injection) once a day. Setmelanotide works by stimulating a hormone in the brain called melanocortin, which helps control hunger and satiety. It is the first and only FDA-approved therapy for these conditions. Setmelanotide has been shown to reduce body weight, BMI, and waist circumference, and improve metabolic parameters, such as insulin and glucose levels.
Setmelanotide, also known by the brand name Imcivree, is a medication used to treat a specific genetic form of obesity in adults. Here's a breakdown of its key aspects:
Function:
- Targets MC4 receptor deficiency: Setmelanotide works by addressing a deficiency in the body's melanocortin 4 (MC4) receptors. These receptors play a crucial role in regulating appetite and energy expenditure. In some people, a genetic mutation can lead to MC4 receptor deficiency, contributing to obesity.
- Promotes satiety and weight loss: By activating the MC4 receptors, Setmelanotide helps individuals feel fuller for longer (increased satiety), leading to reduced calorie intake and potentially promoting weight loss.
Applications:
- Genetic obesity: Setmelanotide is specifically indicated for adults with a confirmed deficiency in the MC4 receptor pathway, linked to genes like leptin receptor (LEPR) or pro-opiomelanocortin (POMC).
Administration:
- Subcutaneous injection: Setmelanotide is administered as a subcutaneous injection, typically once a day.